Identification and validation of dysregulated metabolic pathways in metastatic renal cell carcinoma

Author： White Nicole   Newsted Daniel   Masui Olena   Romaschin Alexander   Siu K.   Yousef George  

Publisher： Springer Publishing Company

ISSN： 1010-4283

Source： Tumor Biology, Vol.35, Iss.3, 2014-03, pp. : 1833-1846

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Sunitinib for metastatic renal cell carcinoma

By Mukherji Deborah   Larkin James   Pickering Lisa  

Future Oncology, Vol. 6, Iss. 9, 2010-09 ,pp. : 1377-1385

Future Medicine

Access to resources Recommend Favorite

Validation of the MSKCC and Heng Risk Criteria Models for Predicting Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib

By Kwon Whi-An   Cho In-Chang   Yu Ami   Nam Byung-Ho   Joung Jae   Seo Ho   Lee Kang   Chung Jinsoo  

Annals of Surgical Oncology, Vol. 20, Iss. 13, 2013-12 ,pp. : 4397-4404

Springer Publishing Company

Access to resources Recommend Favorite

Prognostic Factors of Immunotherapy in Metastatic Renal Cell Carcinoma

By Padrik Peeter  

Medical Oncology, Vol. 20, Iss. 4, 2003-12 ,pp. : 325-334

Humana Press, Inc

Access to resources Recommend Favorite

Axitinib in the treatment of metastatic renal cell carcinoma

By Ho Thai H   Jonasch Eric  

Future Oncology, Vol. 7, Iss. 11, 2011-11 ,pp. : 1247-1253

Future Medicine

Access to resources Recommend Favorite

Current Strategy in the Treatment of Metastatic Renal Cell Carcinoma

By  

Current Cancer Therapy Reviews, Vol. 1, Iss. 2, 2005-06 ,pp. : 127-137

Bentham Science Publishers

Access to resources Recommend Favorite